CL2012000658A1 - Composicion farmaceutica que comprende microesferas entericamente recubiertas que contienen enzimas digestivas tal como lipasa y microesferas no recubiertas entericamente que contienen enzimas digestivas tal como proteasa; forma de dosis; y su uso tratar el dolor de pancreatitis e insuficiencia pancreatica. - Google Patents

Composicion farmaceutica que comprende microesferas entericamente recubiertas que contienen enzimas digestivas tal como lipasa y microesferas no recubiertas entericamente que contienen enzimas digestivas tal como proteasa; forma de dosis; y su uso tratar el dolor de pancreatitis e insuficiencia pancreatica.

Info

Publication number
CL2012000658A1
CL2012000658A1 CL2012000658A CL2012000658A CL2012000658A1 CL 2012000658 A1 CL2012000658 A1 CL 2012000658A1 CL 2012000658 A CL2012000658 A CL 2012000658A CL 2012000658 A CL2012000658 A CL 2012000658A CL 2012000658 A1 CL2012000658 A1 CL 2012000658A1
Authority
CL
Chile
Prior art keywords
digestive enzymes
microspheres containing
enterically
containing digestive
pancreatitis
Prior art date
Application number
CL2012000658A
Other languages
English (en)
Spanish (es)
Inventor
Gopi M Venkatesh
Stepehn Perrett
Ruth Thieroff-Ekerdt
Konstantino Efthymiopoulos
Original Assignee
Aptalis Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43730817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000658(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aptalis Pharmatech Inc filed Critical Aptalis Pharmatech Inc
Publication of CL2012000658A1 publication Critical patent/CL2012000658A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CL2012000658A 2009-09-17 2012-03-15 Composicion farmaceutica que comprende microesferas entericamente recubiertas que contienen enzimas digestivas tal como lipasa y microesferas no recubiertas entericamente que contienen enzimas digestivas tal como proteasa; forma de dosis; y su uso tratar el dolor de pancreatitis e insuficiencia pancreatica. CL2012000658A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24346709P 2009-09-17 2009-09-17

Publications (1)

Publication Number Publication Date
CL2012000658A1 true CL2012000658A1 (es) 2012-09-28

Family

ID=43730817

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000658A CL2012000658A1 (es) 2009-09-17 2012-03-15 Composicion farmaceutica que comprende microesferas entericamente recubiertas que contienen enzimas digestivas tal como lipasa y microesferas no recubiertas entericamente que contienen enzimas digestivas tal como proteasa; forma de dosis; y su uso tratar el dolor de pancreatitis e insuficiencia pancreatica.

Country Status (23)

Country Link
US (2) US8784884B2 (https=)
EP (1) EP2477645B1 (https=)
JP (1) JP5877399B2 (https=)
KR (1) KR101771752B1 (https=)
CN (2) CN102630164B (https=)
AR (1) AR078291A1 (https=)
AU (1) AU2010295494B2 (https=)
BR (1) BR112012005837A8 (https=)
CA (1) CA2774269C (https=)
CL (1) CL2012000658A1 (https=)
CO (1) CO6531419A2 (https=)
ES (1) ES2690661T3 (https=)
HK (1) HK1218886A1 (https=)
IL (2) IL218656A (https=)
MX (1) MX2012003214A (https=)
MY (1) MY161843A (https=)
NZ (1) NZ599143A (https=)
RU (1) RU2570376C2 (https=)
SA (1) SA110310695B1 (https=)
TW (2) TW201639545A (https=)
UY (1) UY32896A (https=)
WO (1) WO2011035079A1 (https=)
ZA (1) ZA201202761B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
JP5966202B2 (ja) 2007-02-20 2016-08-10 アラガン ファーマシューティカルズ インターナショナル リミテッド 安定な消化酵素組成物
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
ES2657673T3 (es) * 2010-10-01 2018-03-06 Aptalis Pharma Limited Formulaciones recubiertas entéricas de pancrelipasa, de baja intensidad
CA2843556A1 (en) * 2011-08-08 2013-02-14 Aptalis Pharma Ltd. Method for dissolution testing of solid compositions containing digestive enzymes
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
CA2920844A1 (en) 2013-08-09 2015-02-12 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
FR3079146B1 (fr) * 2018-03-23 2020-04-17 Karim Ioualalen Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.
US20230138700A1 (en) * 2020-03-30 2023-05-04 Jai WALL Combined animal-derived and synthetically produced pancreatic enzyme replacement therapy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US4447412A (en) * 1983-02-01 1984-05-08 Bilton Gerald L Enzyme-containing digestive aid compostions
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5460812A (en) 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5302400A (en) 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5578304A (en) 1992-06-22 1996-11-26 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
DE4227385A1 (de) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
JP2000505801A (ja) 1996-02-09 2000-05-16 クアドラント・ホールディングズ・ケンブリッジ・リミテッド トレハロースを含む固形製剤
US5750104A (en) 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US20010046493A1 (en) 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
CN1156308C (zh) * 2002-04-19 2004-07-07 北京世诺医药科技有限公司 多酶组合胶囊
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004071374A2 (en) 2003-02-11 2004-08-26 Torrent Pharmaceuticals Limited Once a day orally administered pharmaceutical compositions
WO2005042012A1 (en) * 2003-10-29 2005-05-12 Altus Pharmaceuticals Inc. Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
CA2560613C (en) 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
EP1755656B1 (en) * 2004-05-24 2010-07-07 Novozymes A/S Enzymes for pharmaceutical use
WO2006044529A1 (en) * 2004-10-14 2006-04-27 Altus Pharmaceuticals Inc. Compositions containing lipase; protease and amylase for treating pancreatic insufficiency
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CN101208429A (zh) * 2005-06-24 2008-06-25 诺维信公司 用于药物用途的脂肪酶
US20070025977A1 (en) 2005-07-21 2007-02-01 Mulberg Andrew E Method of treating steatorrhea in infants
KR101555058B1 (ko) 2005-07-29 2015-09-22 애보트 래버러토리즈 게엠베하 살균된 판크레아틴 분말의 제조방법
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
WO2007053619A2 (en) * 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
AU2007267560B2 (en) * 2006-05-26 2010-10-21 Nestec S.A. Methods of use and nutritional compositions of Touchi Extract
US20080199448A1 (en) * 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
JP5966202B2 (ja) 2007-02-20 2016-08-10 アラガン ファーマシューティカルズ インターナショナル リミテッド 安定な消化酵素組成物
US20090117180A1 (en) * 2007-02-20 2009-05-07 Giovanni Ortenzi Stable digestive enzyme compositions
EP2328566A1 (en) 2008-09-30 2011-06-08 DSM IP Assets B.V. Enzyme composition and application thereof in the treatment of pancreatic insufficiency

Also Published As

Publication number Publication date
MX2012003214A (es) 2012-08-01
BR112012005837A2 (pt) 2017-05-30
TW201639545A (zh) 2016-11-16
HK1218886A1 (zh) 2017-03-17
CN102630164A (zh) 2012-08-08
JP5877399B2 (ja) 2016-03-08
ZA201202761B (en) 2012-12-27
KR20120100915A (ko) 2012-09-12
UY32896A (es) 2011-02-28
TWI572372B (zh) 2017-03-01
CO6531419A2 (es) 2012-09-28
SA110310695B1 (ar) 2014-11-26
RU2570376C2 (ru) 2015-12-10
TW201113052A (en) 2011-04-16
JP2013505255A (ja) 2013-02-14
EP2477645A4 (en) 2014-06-25
KR101771752B1 (ko) 2017-08-25
RU2012113253A (ru) 2013-10-27
CA2774269A1 (en) 2011-03-24
EP2477645A1 (en) 2012-07-25
IL218656A0 (en) 2012-05-31
CN102630164B (zh) 2015-09-16
IL218656A (en) 2017-12-31
ES2690661T3 (es) 2018-11-21
US8784884B2 (en) 2014-07-22
CA2774269C (en) 2017-03-21
US20140287035A1 (en) 2014-09-25
WO2011035079A1 (en) 2011-03-24
CN105214073A (zh) 2016-01-06
AR078291A1 (es) 2011-10-26
NZ599143A (en) 2014-05-30
EP2477645B1 (en) 2018-08-15
AU2010295494B2 (en) 2014-09-25
BR112012005837A8 (pt) 2017-10-10
US20110064799A1 (en) 2011-03-17
US20160051472A9 (en) 2016-02-25
IL245875A0 (en) 2016-07-31
AU2010295494A1 (en) 2012-03-29
MY161843A (en) 2017-05-15

Similar Documents

Publication Publication Date Title
CL2012000658A1 (es) Composicion farmaceutica que comprende microesferas entericamente recubiertas que contienen enzimas digestivas tal como lipasa y microesferas no recubiertas entericamente que contienen enzimas digestivas tal como proteasa; forma de dosis; y su uso tratar el dolor de pancreatitis e insuficiencia pancreatica.
BRPI1013388A2 (pt) composição de limpeza que compreende uma alfa-amilase e uma protease e método de limpeza de um tecido ou superficie dura
BRPI0907826A2 (pt) inibidores heterocíclicos de estearoil-coa desaturase
MX2012007684A (es) Modificacion covalente ligando dirigida de proteina.
TN2009000045A1 (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level
CU23914B1 (es) DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL CoA
CL2011002432A1 (es) Composicion que comprende al menos una enzima digestiva y al menos un portador, en donde el portador comprende celulosa microcristalina que tiene un tamaño de particulas mayor que 100 um; una forma de dosificacion; el envase que la contiene; un proceso para preparar la composicion; y sus usos.
GB2480987B (en) Enzyme delivery systems and methods of preparations and use
BR112013026494A2 (pt) composto, composição farmacêutica, método para tratar condição
BR112015007083A2 (pt) inibidores de histona demetilases
ES2572160T3 (es) Una nueva preparación farmacéutica para preeclampsia
GB2511713A (en) Methods of treating behavioral symptoms of neurological and mental disorders
MX2009011215A (es) Derivados de triazolopiridina carboxamida, su preparacion y su aplicacion terapeutica.
BR112014027942A2 (pt) dispersão de pó pró-lipossomal; composição farmacêutica; forma de dosagem oral; e método para tratar um indivíduo que necessite de terapia de testosterona
AR087847A1 (es) Composiciones detergentes que comprenden enzima y tensioactivo
BR112019024566A2 (pt) inibidores de pirazol magl
BRPI0922653B8 (pt) uso de uma lipase bacteriana do tipo pseudomonas em solução aquosa
PH12013500485A1 (en) Fabric treatment compositions comprising target benefit agents
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
IN2012DN01913A (https=)
CO6280488A2 (es) Combinacion farmaceutica
UY34896A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
MX346316B (es) Formulacion farmaceutica o nutraceutica.
PH12015501131A1 (en) Fibrinolytic compositions comprising bromelain and nattokinase for the prevention and treatment of phlebothrombotic states
ECSP13012765A (es) Combinación y composición para el tratamiento de obesidad